

Erika Borlenghi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4629557/publications.pdf>

Version: 2024-02-01

20
papers

1,353
citations

759233

12
h-index

752698

20
g-index

20
all docs

20
docs citations

20
times ranked

2315
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL). <i>Journal of Geriatric Oncology</i> , 2021, 12, 550-556.	1.0	12
2	Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. <i>Blood Advances</i> , 2021, 5, 4370-4379.	5.2	5
3	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020, 34, 914-918.	7.2	46
4	Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. <i>Cancer</i> , 2020, 126, 5069-5076.	4.1	69
5	Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1304-1313.	4.1	1
6	Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07. <i>Blood Cancer Journal</i> , 2020, 10, 119.	6.2	29
7	Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia. <i>Hematological Oncology</i> , 2020, 38, 754-762.	1.7	9
8	Impact of Covid-19 on the treatment of acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2254-2256.	7.2	33
9	Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning. <i>British Journal of Haematology</i> , 2020, 190, e304-e307.	2.5	1
10	Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy. <i>Hematological Oncology</i> , 2019, 37, 447-455.	1.7	25
11	Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. <i>Blood Advances</i> , 2019, 3, 1103-1117.	5.2	23
12	Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia. <i>Leukemia</i> , 2019, 33, 1598-1607.	7.2	15
13	Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL). <i>American Journal of Hematology</i> , 2018, 93, E54-E57.	4.1	1
14	Acquired cyclic neutropenia associated with cocaine-induced anti-neutrophil cytoplasmic antibodies binding to human neutrophil elastase. <i>American Journal of Hematology</i> , 2018, 93, E227-E229.	4.1	2
15	Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 605-612.	1.6	299
16	Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1983-1987.	2.0	77
17	Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 786-793.	3.5	27
18	Validating the Patient's "Fitness" Criteria Proposed to Guide Treatment Decision in Elderly AML: a Multicenter Study on a Population-Based Series of 362 Patients By the Network "Rete Ematologica Lombarda" (REL). <i>Blood</i> , 2014, 124, 279-279.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood, 2010, 116, 3171-3179.	1.4	290
20	Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood, 2009, 113, 4153-4162.	1.4	387